Nexavar receives final appraisal for primary liver cancer
NICE has released a Final Appraisal Document recommending Nexavar for the treatment of patients with advanced hepatocellular carcinoma...
List view / Grid view
NICE has released a Final Appraisal Document recommending Nexavar for the treatment of patients with advanced hepatocellular carcinoma...
Bayer have announced the European Commission has granted marketing authorisation for Stivarga...
11 March 2014 | By Amgen
Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma...
22 November 2013 | By Amgen
First and only FDA-approved treatment option for patients with this type of thyroid cancer...